For detailed recommendations, see the CDC's Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States, 2016 (Updated May 2018) and Interim Statement Regarding Potential Fetal Harm from Exposure to Dolutegravir - Implications for HIV Post-exposure Prophylaxis (PEP).